A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2018
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 31 May 2018 Planned End Date changed from 30 Jun 2019 to 1 Jan 2020.
- 22 Feb 2018 Planned primary completion date changed from 30 Jun 2019 to 1 Jan 2019.
- 10 Jan 2018 Planned End Date changed from 1 Jan 2019 to 30 Jun 2019.